The data include gene expression profiles, mutations, methylation patterns, survival outcomes, and immune infiltration related to CSF2RB, specifically in breast cancer, and are compared to acute myeloid leukemia as a control since the role of CSF2RB in AML is well-established. This evidence concerns the gene CSF2RB and breast carcinoma.